- Home
- MNMD vs ZKH Comparison
MNMD vs ZKH Comparison
Compare MNMD & ZKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- ZKH
- Stock Information
- Founded
- MNMD 2019
- ZKH 1998
- Country
- MNMD United States
- ZKH China
- Employees
- MNMD N/A
- ZKH N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- ZKH
- Sector
- MNMD Health Care
- ZKH
- Exchange
- MNMD Nasdaq
- ZKH Nasdaq
- Market Cap
- MNMD 509.2M
- ZKH 496.1M
- IPO Year
- MNMD N/A
- ZKH 2023
- Fundamental
- Price
- MNMD $7.17
- ZKH $3.15
- Analyst Decision
- MNMD Strong Buy
- ZKH Buy
- Analyst Count
- MNMD 7
- ZKH 1
- Target Price
- MNMD $26.29
- ZKH $4.00
- AVG Volume (30 Days)
- MNMD 1.2M
- ZKH 22.1K
- Earning Date
- MNMD 08-12-2025
- ZKH 08-21-2025
- Dividend Yield
- MNMD N/A
- ZKH N/A
- EPS Growth
- MNMD N/A
- ZKH N/A
- EPS
- MNMD N/A
- ZKH N/A
- Revenue
- MNMD N/A
- ZKH $1,217,705,644.00
- Revenue This Year
- MNMD N/A
- ZKH $11.72
- Revenue Next Year
- MNMD N/A
- ZKH $10.57
- P/E Ratio
- MNMD N/A
- ZKH N/A
- Revenue Growth
- MNMD N/A
- ZKH 2.24
- 52 Week Low
- MNMD $4.70
- ZKH $2.50
- 52 Week High
- MNMD $10.44
- ZKH $4.10
- Technical
- Relative Strength Index (RSI)
- MNMD 52.28
- ZKH 54.57
- Support Level
- MNMD $6.40
- ZKH $3.02
- Resistance Level
- MNMD $7.20
- ZKH $3.18
- Average True Range (ATR)
- MNMD 0.43
- ZKH 0.17
- MACD
- MNMD -0.03
- ZKH -0.00
- Stochastic Oscillator
- MNMD 76.03
- ZKH 80.00
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.